-
Rise across the board! TOP10 brands in the 27 billion insulin market released
A few days ago, Ganli Pharmaceutical's first second-generation insulin was approved for listing, and its leading position has been consolidated.
2021-05-31 09:52 -
Rise across the board! TOP10 brands in the 27 billion insulin market released
A few days ago, Ganli Pharmaceutical's first second-generation insulin was approved for listing, and its leading position has been consolidated.
2021-05-28 16:54 -
GlaxoSmithKline receives antitrust penalty: the agreement to delay the entry of generic drugs is ill...
A few days ago, the website of the State Administration for Market Regulation released a news about the penalties imposed by the UK Competition and Ma...
2021-05-27 13:43 -
In the first quarter of 2021, these drugs are the best sellers!
The top three products: AbbVie’s adalimumab sales were US$4.867 billion in the first quarter; Merck’s pembrolizumab sold a total of US$3.899 billion...
2021-05-25 18:14 -
Renfu Pharmaceutical's Class 1 New Drug Propofol Disodium Phosphate for Injection Approved
NMPA released the information of drug approval documents pending on May 24, 2021. Among them, Yichang Renfu Pharmaceutical Co., Ltd., a new drug of Cl...
2021-05-24 18:07 -
The peak season is approaching, the veterinary raw material drug market may rebound!
The production capacity of florfenicol raw materials is limited or there may be an oversold rebound.
2021-05-21 14:08 -
Big pharma seizing new opportunities in China therapeutics market
As China becomes the most important market for multinational pharmaceutical companies and the government’s Healthy China 2030 policy shifts into high...
2021-05-13 13:39 -
With $26 billion sales blessing, Pfizer will return to the top 1 pharmaceutical company?
Humira, whose sales in 2020 has approached 20 billion U.S. dollars, is not only being chased by K medicine, but also being challenged by Pfizer.
2021-05-13 10:48 -
Neratinib Plus Fulvestrant Combination Does Not Meet Efficacy Criteria for Metastatic Breast Cancer
The clinical benefit rate (CBR) of the neratinib (Nerlynx) plus fulvestrant (Faslodex) combination treatment did not meet the predefined efficacy thre...
2021-05-11 11:56 -
EMA starts evaluating use of Olumiant（Baricitinib） in hospitalised COVID-19 patients requiring sup...
EMA has started evaluating an application to extend the use of Olumiant (baricitinib) to include treatment of COVID-19 in hospitalised patients from 1...
2021-05-11 11:53
Hot News
- ExxonMobil Launches $10 Billio... Jul 17, 2025
- Global MDI/TDI Plants Enter Pe... Jul 23, 2025
- Europe Faces Unprecedented Pet... Jul 23, 2025
- BASF Launches Second Round of ... Jul 24, 2025
- Guangdong Jieyang Puts into Op... Jul 16, 2025
Related Products
Related Producers
